Renaissance Technologies LLC Trims Position in USANA Health Sciences, Inc. (NYSE:USNA)

Renaissance Technologies LLC reduced its position in USANA Health Sciences, Inc. (NYSE:USNA - Free Report) by 3.5% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,179,163 shares of the company's stock after selling 43,200 shares during the quarter. Renaissance Technologies LLC owned about 6.19% of USANA Health Sciences worth $53,345,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of USNA. Quest Partners LLC acquired a new position in USANA Health Sciences in the 4th quarter valued at about $66,000. CWM LLC increased its holdings in shares of USANA Health Sciences by 21.8% in the first quarter. CWM LLC now owns 1,543 shares of the company's stock valued at $75,000 after purchasing an additional 276 shares during the period. BOKF NA raised its stake in shares of USANA Health Sciences by 274.5% during the first quarter. BOKF NA now owns 2,771 shares of the company's stock worth $133,000 after purchasing an additional 2,031 shares during the last quarter. Trexquant Investment LP purchased a new stake in shares of USANA Health Sciences during the fourth quarter worth approximately $266,000. Finally, Price T Rowe Associates Inc. MD lifted its holdings in shares of USANA Health Sciences by 9.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 5,849 shares of the company's stock worth $284,000 after purchasing an additional 494 shares during the period. 54.25% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, insider Paul A. Jones sold 6,266 shares of the stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $38.38, for a total value of $240,489.08. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other USANA Health Sciences news, Director John Turman Fleming sold 1,000 shares of the firm's stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $44.43, for a total transaction of $44,430.00. Following the completion of the transaction, the director now owns 2,503 shares of the company's stock, valued at $111,208.29. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Paul A. Jones sold 6,266 shares of the company's stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $38.38, for a total value of $240,489.08. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 7,940 shares of company stock worth $311,670. 0.33% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

USNA has been the topic of several recent research reports. StockNews.com cut shares of USANA Health Sciences from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, July 24th. DA Davidson cut their price target on shares of USANA Health Sciences from $46.00 to $38.00 and set a "neutral" rating for the company in a report on Thursday, July 25th.

USANA Health Sciences Price Performance

Shares of USNA stock traded down $0.14 during trading hours on Wednesday, reaching $39.82. 66,826 shares of the company's stock were exchanged, compared to its average volume of 78,197. The company's 50 day moving average is $41.20 and its two-hundred day moving average is $44.58. The company has a market cap of $758.61 million, a P/E ratio of 12.40, a price-to-earnings-growth ratio of 1.28 and a beta of 0.90. USANA Health Sciences, Inc. has a 1 year low of $36.05 and a 1 year high of $60.90.

USANA Health Sciences (NYSE:USNA - Get Free Report) last announced its quarterly earnings results on Tuesday, July 23rd. The company reported $0.54 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.65 by ($0.11). The company had revenue of $212.87 million during the quarter, compared to analysts' expectations of $218.64 million. USANA Health Sciences had a net margin of 6.29% and a return on equity of 11.13%. During the same quarter in the prior year, the business earned $0.89 EPS. As a group, analysts predict that USANA Health Sciences, Inc. will post 2.5 EPS for the current fiscal year.

USANA Health Sciences Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.